NICE UK recommends Keytruda with carboplatin and paclitaxel for metastatic squamous non-small-cell lung cancer – Merck Inc

NICE (UK): Keytruda (pembrolizumab), from Merck Inc. with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if their tumours express PD?L1 with a tumour proportion score of 0% to 49%, if their tumours express PD?L1 with a tumour proportion score of 50% or more and they need urgent clinical […]